Cempra Holdings LLC Lowered to “Neutral” at Zacks (CEMP)
Cempra Holdings LLC (NASDAQ:CEMP) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, AnalystRatingsNetwork.com reports. They currently have a $10.00 price target on the stock. Zacks‘ price objective would indicate a potential upside of 11.23% from the company’s current price.
Separately, analysts at Stifel Nicolaus raised their price target on shares of Cempra Holdings LLC (NASDAQ:CEMP) from $11.00 to $13.00 in a research note to investors on Wednesday, July 31st. They now have a “buy” rating on the stock.
One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has issued a strong buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $11.10.
Cempra Holdings LLC (NASDAQ:CEMP) traded down 2.07% on Wednesday, hitting $8.99. The stock had a trading volume of 51,959 shares. Cempra Holdings LLC has a one year low of $5.26 and a one year high of $9.54. The stock has a 50-day moving average of $8.69 and a 200-day moving average of $7.46. The company’s market cap is $298.3 million.
Cempra Holdings LLC (NASDAQ:CEMP) last posted its quarterly earnings results on Tuesday, July 30th. The company reported ($0.16) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.42) by $0.26. The company had revenue of $4.60 million for the quarter, compared to the consensus estimate of $5.13 million. During the same quarter in the prior year, the company posted ($0.45) earnings per share. The company’s quarterly revenue was up 4599900.0% on a year-over-year basis. On average, analysts predict that Cempra Holdings LLC will post $-1.25 earnings per share for the current fiscal year.
Cempra, Inc, formerly Cempra Holdings, LLC, is a development-stage and clinical-stage pharmaceutical company focused on developing antibiotics to meet medical needs in the treatment of bacterial infectious diseases, particularly respiratory tract infections and chronic and acute staphylococcal infections.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.